Scientists Decode Hidden Fault Line Clues That Could Predict the Next Big Earthquake
New research uncovers a surprising clue in earthquake forecasting: tiny curved scratches on fault planes. These marks reveal ...
FDA approves Journavx, the first new painkiller in over two decades
The new drug will carry a list price of $15.50 per pill, making it many times more expensive than comparable opioids.
At $31 a day, is Vertex’s new non-addictive painkiller worth the price?
Will people with acute pain want a new painkiller whose list price is $15.50 a pill when a generic prescription drug is at ...
Vertex Pharmaceuticals' SWOT analysis: cystic fibrosis leader faces pipeline challenges
Vertex Pharmaceuticals (NASDAQ:VRTX), a global biotechnology company with a market capitalization of $119.1 billion known for its transformative cystic fibrosis (CF) treatments, finds itself at a ...
verywellhealth1d
New FDA-Approved Painkiller Is a Safer Alternative to Opioids
The FDA has approved a new type of painkiller that doesn't come with the risks of addiction and overdose associated with opioids.
FDA approves new pain medicine as opioid alternative. What to know about Journavx
The FDA has approved Journavx, a pain medication, offering a safer alternative to opioids. Learn about its benefits and side ...
BioPharma Dive1d
A new, non-opioid pain drug is here. Getting it to patients could be agony.
After decades of research, Vertex Pharmaceuticals now has an approved pain medication. Can one of the world’s most powerful ...
What's Happening With VRTX Stock?
With a rise in Trikafta demand, the investors have assigned a higher valuation multiple for VRTX stock. The increase in VRTX ...
kffhealthnews1d
From KFF Health News - Latest Stories:
Cigna To Reform Prior Authorization, Provider Services In 2025 The Cigna Group will spend up to $150 million to reform its prior authorization, patient advocacy and provider services this year, CEO ...